Cargando…

Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients

OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wen-Xin, Jia, Rui, Jin, Xue-Yuan, Li, Xiaoyan, Zhou, Shuang-Nan, Zhang, Xiao-Ning, Zhou, Chun-Bao, Wang, Fu-Sheng, Fu, Junliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899895/
https://www.ncbi.nlm.nih.gov/pubmed/36756119
http://dx.doi.org/10.3389/fimmu.2023.1121778
_version_ 1784882732259606528
author Wang, Wen-Xin
Jia, Rui
Jin, Xue-Yuan
Li, Xiaoyan
Zhou, Shuang-Nan
Zhang, Xiao-Ning
Zhou, Chun-Bao
Wang, Fu-Sheng
Fu, Junliang
author_facet Wang, Wen-Xin
Jia, Rui
Jin, Xue-Yuan
Li, Xiaoyan
Zhou, Shuang-Nan
Zhang, Xiao-Ning
Zhou, Chun-Bao
Wang, Fu-Sheng
Fu, Junliang
author_sort Wang, Wen-Xin
collection PubMed
description OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected. RESULTS: At week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48. CONCLUSIONS: The serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets.
format Online
Article
Text
id pubmed-9899895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98998952023-02-07 Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients Wang, Wen-Xin Jia, Rui Jin, Xue-Yuan Li, Xiaoyan Zhou, Shuang-Nan Zhang, Xiao-Ning Zhou, Chun-Bao Wang, Fu-Sheng Fu, Junliang Front Immunol Immunology OBJECTIVE: The aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients. METHODS: Seventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected. RESULTS: At week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48. CONCLUSIONS: The serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets. Frontiers Media S.A. 2023-01-23 /pmc/articles/PMC9899895/ /pubmed/36756119 http://dx.doi.org/10.3389/fimmu.2023.1121778 Text en Copyright © 2023 Wang, Jia, Jin, Li, Zhou, Zhang, Zhou, Wang and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Wen-Xin
Jia, Rui
Jin, Xue-Yuan
Li, Xiaoyan
Zhou, Shuang-Nan
Zhang, Xiao-Ning
Zhou, Chun-Bao
Wang, Fu-Sheng
Fu, Junliang
Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title_full Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title_fullStr Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title_full_unstemmed Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title_short Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
title_sort serum cytokine change profile associated with hbsag loss during combination therapy with peg-ifn-α in nas-suppressed chronic hepatitis b patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899895/
https://www.ncbi.nlm.nih.gov/pubmed/36756119
http://dx.doi.org/10.3389/fimmu.2023.1121778
work_keys_str_mv AT wangwenxin serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT jiarui serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT jinxueyuan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT lixiaoyan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT zhoushuangnan serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT zhangxiaoning serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT zhouchunbao serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT wangfusheng serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients
AT fujunliang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients